Ocular allergy/inflammation:

Indications for: LOTEMAX OPH OINT

Post-op inflammation after ocular surgery.

Clinical Trials:

  • The efficacy of Lotemax Ointment was evaluated in 2 independent, randomized, multicenter, double-masked, parallel-group, vehicle-controlled studies in 805 patients who met a protocol-specified threshold amount of anterior chamber inflammation.

  • Lotemax was more effective in resolving anterior chamber inflammation and pain following cataract surgery compared with vehicle.

  • At post-operative Day 8, Lotemax achieved a statistically significant higher incidence of complete clearing of anterior chamber cells and flare (24-32% vs 11-14%) and a statistically significant higher incidence of patients who were pain-free (73-78% vs 41-45%). 

Adult Dosage:

Apply a small amount (approx. ½ inch ribbon) into the affected eye(s) 4 times daily beginning 24hrs after surgery, continue for 2wks post-op.

Children Dosage:

Not established.

LOTEMAX OPH OINT Contraindications:

Ocular fungal, viral, or mycobacterial infections.

LOTEMAX OPH OINT Warnings/Precautions:

Reevaluate if no improvement after 2 days. Prescribe initially and renew only after appropriate exam. Corneal or scleral thinning. Glaucoma. History of herpes simplex. Monitor IOP and for secondary infections in prolonged therapy (>10 days). Avoid abrupt cessation. Contact lenses (remove during therapy and when eyes are inflamed). Pregnancy. Nursing mothers.

LOTEMAX OPH OINT Classification:


Adverse Reactions:

Local reactions (eg, blurred vision, burning, itching, dry eye), photophobia, headache, rhinitis, pharyngitis. May mask or exacerbate ocular infections. Prolonged use may increase: IOP, optic nerve damage, visual acuity and field defects, cataract formation, corneal perforation. May delay healing and increase bleb formation after cataract surgery; also, Oint/Gel: anterior chamber inflammation, conjunctival hyperemia, corneal edema, eye pain.



Drug Elimination:


How Supplied:

Susp—5mL, 10mL, 15mL, Oint—3.5g; Gel—5g